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A B S T R A C T
Age has been shown to have an impact on both grey (GM) and white matter (WM) volume, with a steeper slope
of age-related decline in schizophrenia compared to healthy controls. In schizophrenia, the relation between age
and brain volume is further complicated by factors such as lower intelligence, antipsychotic medication, and
cannabis use, all of which have been shown to have independent eﬀects on brain volume.
In a study of ﬁrst-episode, antipsychotic-naïve schizophrenia patients (N=54) and healthy controls
(N= 56), we examined the eﬀects of age on whole brain measures of GM and WM volume, and whether these
relationships were moderated by schizophrenia and intelligence (IQ). Secondarily, we examined lifetime can-
nabis use as a moderator of the relationship between age and brain volume.
Schizophrenia patients had lower GM volumes than healthy controls but did not diﬀer on WM volume. We
found an age eﬀect on GM indicating that increasing age was associated with lower GM volumes, which did not
diﬀer between groups. IQ did not have a direct eﬀect on GM, but showed a trend-level interaction with age,
suggesting a greater impact of age with lower IQ. There were no age eﬀects on WM volume, but a direct eﬀect of
IQ, with higher IQ showing an association with larger WM volume. Lifetime cannabis use did not alter these
ﬁndings signiﬁcantly.
This study points to eﬀects of schizophrenia on GM early in the illness, before antipsychotic treatment is
initiated, suggesting that WM changes may occur later in the disease process.
1. Introduction
Patients with schizophrenia have been found to have a steeper re-
gression slope of age-related changes in brain volume compared to
healthy people (Hulshoﬀ Pol et al., 2002). A meta-analysis of long-
itudinal studies in schizophrenia reported progressive changes in both
grey (GM) and white matter (WM) volume over time (Olabi et al.,
2011). This progressive loss of brain volume was found to be particu-
larly steep in the ﬁrst years after illness onset, suggesting that the un-
derlying pathological and/or environmental factors may be accelerated
in the early stages of the illness (Andreasen et al., 2011; Sun et al.,
2009; Vita et al., 2012). The trajectory of brain volume changes with
age in schizophrenia appears to be more severe than that related to
normal aging before 45 years of age, after which brain volume in pa-
tients appears to decrease at a normal rate (Van Haren et al., 2008).
Further, diﬀerences in trajectories of GM and WM over age suggest that
reductions in WM occur later than in GM (Cropley et al., 2017).
Brain volume is aﬀected by several genetic and environmental
factors, the relative impact of which changes with age (Batouli et al.,
2014). During normal brain maturation, there is an increase of total
brain volume throughout childhood, with evidence of a gradual de-
crease after age 13, relative stability in young adulthood, and a slight
decrease starting again in the mid-30s, which accelerates in late life,
from around age 60 (Hedman et al., 2012). The timing of normal ma-
turation diﬀers between GM and WM, with a peak of GM volume in the
mid-20s and of WM in the late 30s (Lebel et al., 2012). The relationship
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between age and brain volume in schizophrenia is complex, since en-
vironmental factors, including antipsychotic medication and cannabis
use, also have independent eﬀects on brain structure and function (Van
Van Haren et al., 2013). Reductions in global brain volume have been
found in ﬁrst-episode, medication-naïve patients with schizophrenia,
but to a smaller extent than in medicated patients, indicating that brain
volume reductions are present at illness onset, with evidence of further
progressive loss due to the eﬀects of the illness and/or impact of
treatment (Ansell et al., 2015; Haijma et al., 2013).
Another factor related to brain volume changes with age is in-
telligence (IQ). In healthy people a signiﬁcant positive correlation be-
tween intelligence and brain volume is found (McDaniel, 2005), with
the covariance ranging from small (Pietschnig et al., 2015) to sub-
stantial (Ritchie, 2015). A similar, and perhaps stronger relationship
has been found in schizophrenia patients (Rais et al., 2012).
Throughout normal brain development and maturation, brain volume
increase with age is positively correlated with IQ (Brans et al., 2010;
Shaw et al., 2006). Similarly, decrease in brain volume across adult-
hood is negatively related to IQ, with evidence of shared heritability of
brain volume changes and IQ across the lifespan (Brans et al., 2010;
Brouwer et al., 2014). In schizophrenia, age-related decrease in brain
volume has been found to be related to relative progression of IQ def-
icits (Kubota et al., 2015), but it is diﬃcult to disentangle this re-
lationship from medication eﬀects.
In the present study, we examined antipsychotic-naïve ﬁrst-episode
schizophrenia patients at ﬁrst presentation, thus avoiding the con-
founding eﬀects of medication and chronicity. The primary aim was to
examine if the eﬀect of age on total GM and WM volumes is moderated
by schizophrenia and intelligence, or their interaction at this early stage
of the illness. A secondary aim was to examine the contribution of
lifetime cannabis use on any age-related eﬀects of ﬁrst-episode schi-
zophrenia and intelligence on brain volume. These aims were examined
in a cross-sectional study of antipsychotic-naïve ﬁrst-episode schizo-
phrenia patients and healthy controls. Based on previous ﬁndings we
hypothesized a more pronounced eﬀect of age on GM than WM volume
in ﬁrst episode schizophrenia patients compared to healthy controls,
and expected an interaction between the eﬀects of schizophrenia and
lower intelligence on GM volume.
2. Materials and methods
The study was approved by the Danish National Committee on
Biomedical Research Ethics (H-D-2008-088) and the Danish Data
Protection Agency (2008-41-2701) and conducted in accordance with
the Declaration of Helsinki II. All participants provided written in-
formed consent before inclusion.
As part of a multimodal cohort study, both in- and out-patients aged
18 to 45 years presenting with a ﬁrst-episode of schizophrenia were
referred from Mental Health Services in the Capital Region of Denmark
from December 2008 to April 2014. The cohort was initially presented
in Nielsen et al. (2012), and there is partial overlap with aspects of data
presented on cortical thickness, WM and psychotic symptoms, and
machine learning (Bak et al., 2017; Ebdrup et al., 2016; Jessen et al.,
2018), see also www.cinsr.dk for other publications from this cohort.
Patients fulﬁlling criteria of an ICD-10 diagnosis of schizophrenia were
included. Healthy controls were recruited from the community through
a webpage (www.forsoegsperson.dk). Exclusion criteria for all partici-
pants were: Any current or previous treatment with antipsychotic
medication; treatment with antidepressants within the past month;
serious somatic or neurological illness; a history of head injury with loss
of consciousness> 5min; and a current ICD-10 diagnosis of drug de-
pendence. Current occasional drug use was accepted (assessed by in-
terview and urine screening). Additional exclusion criteria speciﬁc to
healthy controls were: Previous or current psychiatric illness, or psy-
chiatric illness in ﬁrst-degree relatives. Benzodiazepines were not al-
lowed on days of examinations.
Diagnosis at inclusion was based on the diagnostic interview
Schedules for Clinical Assessment in Neuropsychiatry (Wing et al.,
1990) (SCAN), version 2.1. Psychopathology was assessed with the
Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987).
Lifetime cannabis use was rated on a 5-point ordinal scale (0=Never
tried, 1= Tried a few times, 2=Use regularly, 3=Abuse, 4=De-
pendency).
A total of 69 patients and 67 healthy controls were recruited. Fifty-
four patients and 56 healthy controls had full magnetic resonance
imaging (MR) and Wechsler Adult Intelligence Scale, 3rd ed. (WAIS-III)
datasets and were included in the present analyses. The healthy con-
trols were matched to patients on gender, age and parental socio-
economic status, thus there were no signiﬁcant group diﬀerences on
these measures (see Table 1).
Four subtests from the Danish version of the WAIS-III (Wechsler,
1997); Vocabulary, Similarities, Block Design and Matrix Reasoning
were combined to provide a measure of intelligence quotient (IQ).
These 4 subtests have been shown to correlate strongly with Full Scale
IQ (Axelrod, 2002). Raw scores were normalized to z-scores using the
healthy control group as reference (Table 1).
Structural MR was performed using a Phillips Achieva 3.0 whole
body MRI scanner (Phillips Healthcare) with an 8-channel SENSE head
coil (Invivo). Three-dimensional high-resolution T1 weighted images
were acquired with repetition time 10msec, echo time 4.6ms, ﬂip
angle 8°, and voxel size 0.79× 0.79×0.80mm3. Total GM and WM
volumes were estimated using SIENAX, part of the FSL software
(Table 2). This procedure estimates raw brain volumes as well as brain
volumes after spatially normalizing the intracranial volume (ICV) to
Table 1
Demographic and clinical data for antipsychotic-naive schizophrenia patients
and healthy controls. Results from analyses of group diﬀerences.
Antipsychotic-naïve
schizophrenia patients
Healthy
controls
Demographic data
Mean age in years; mean
(SD)
24.69 (5.93) 24.91 (5.61)
Male gender; N (%) 31 (57) 33 (59)
Years of education; mean
(SD)⁎⁎
12.23 (2.49) 14.64 (2.57)
Parental SES (A/B/C)a 11/30/10 17/28/10
Cannabis (0/1/2/3)a,⁎⁎ 11/28/11/4 28/21/5/0
IQ; mean z-score (SD)⁎⁎ −1.04 (1.63) 0.00 (1.00)
Clinical data
PANSS positive; mean (SD) 20.35 (4.1)
PANSS negative; mean (SD) 20.96 (7.55)
PANSS general, mean (SD) 42.02 (8.90)
PANSS total; mean (SD) 83.33 (16.88)
No signiﬁcant group diﬀerences: Gender (χ2= 0.026, df= 1, p=0.872);
Parental SES (χ2= 1.205, df= 2, p=0.547).
a N varies due to missing data: Parental SES (patient N=51/control
N= 55); Cannabis use (patient N=54/control N=54).
⁎⁎ Group diﬀerences p≤ 0.001: Years of education (F(108)= 0.513,
p < 0.00001); IQ (F(86.691)= 10.189, p < 0.001); Cannabis use (Fisher's
exact test= 14.359, p=0.001).
Table 2
Grey and white matter volume in antipsychotic-naive schizophrenia patients
and healthy controls.
Volume in mm3 Antipsychotic-naïve
schizophrenia patients
N=54
Healthy controls
N=56
Grey matter volume;
mean (SD)
862.91 (49.79) 882.10 (52.59)
White matter volume;
mean (SD)
755.67 (39.47) 763.02 (47.72)
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that of a reference space. In the present work we primarily used the
normalized brain volumes in order to minimize the eﬀects of gender
related to body-size. Gender was found to have no signiﬁcant eﬀect on
normalized brain volumes and was not entered into the analyses.
PANSS symptom scores and duration of untreated illness did not cor-
relate with GM or WM volumes in the patient group and were not in-
cluded in analyses. Assessments (e.g. inclusion interviews, psycho-
pathology ratings, MR scans and cognitive tests) were carried out
within a 2-week period before treatment initiation.
All statistical analyses were carried out using SPSS 24.0. All ana-
lyses used two-tailed levels of signiﬁcance set at p < 0.05. Normality
was examined using the Shapiro-Wilk test of normality. Diﬀerences in
characteristics between groups were tested with t-tests for continuous
data and Pearson's χ2 for nominal data. To examine whether group
(schizophrenia vs healthy controls) and intelligence moderated the ef-
fect of age on brain volume we applied a multiple regression model. The
main eﬀects of age, IQ and group were estimated along with the
moderating 2-way interactions (age ∗ IQ, and age ∗ group) and 3-way
interactions (age ∗ IQ ∗ group). The analyses were performed twice,
using total GM or total WM. Parameter values were estimated with
bootstrap sampling (10,000 samples) on centered variables. In sec-
ondary analyses we examined the eﬀect of including cannabis use in the
model (adding main eﬀect of cannabis use, age ∗ cannabis use, and
age ∗ cannabis use ∗ group interactions).
3. Results
The patient sample was 57% male, mean age 24.7 ± 5.9 years; the
matched healthy control sample was 59% male, mean age
24.9 ± 5.6 years. As expected, healthy controls had signiﬁcantly more
years of education compared to patients (F(108)= 0.513, p < 0.001).
With a mean total PANSS score of 83.3 ± 16.9, the patients were
‘markedly ill’ (Leucht et al., 2005). IQ was signiﬁcantly lower in pa-
tients compared to controls with an average z-score of −1.04 SD (F
(86.691)= 10.189, p < 0.001), which is similar to previous ﬁrst-epi-
sode studies (Mesholam-Gately et al., 2009). Lifetime cannabis use was
signiﬁcantly more prevalent in the patient group than in the healthy
controls (Fisher's exact test= 14.359, p=0.001).
There was a signiﬁcant eﬀect of age (p < 0.001) and group
(p=0.04) on GM volume (Fig. 1). While IQ did not have an in-
dependent eﬀect on grey matter, there was a trend level age*IQ inter-
action (p=0.07). The interaction suggested a steeper negative slope
between GM and age with lower IQ scores. There was no group*age
interaction (Table 3). There was no direct eﬀect of cannabis use on GM
volume and no signiﬁcant interaction by group.
There was no direct eﬀect of age or group on WM, but a signiﬁcant
eﬀect of IQ (p=0.04) (Figs. 2 and 3). There were no signiﬁcant in-
teractions (Table 3). Cannabis did not contribute to the model and there
were no direct or interaction eﬀects of cannabis on WM.
4. Discussion
In this study of antipsychotic-naïve ﬁrst-episode patients with
schizophrenia, we examined the eﬀect of age at ﬁrst presentation on
global measures of GM and WM and examined whether this eﬀect was
moderated by IQ. Patients had lower GM volumes compared with
healthy controls. Increasing age was associated with a signiﬁcantly
lower GM volume in both patients and controls, with no signiﬁcant
diﬀerence between groups in this relationship. While IQ had no sig-
niﬁcant eﬀect on GM, there was a trend-level IQ by age eﬀect on GM,
suggesting that increasing age had a greater impact on GM volume in
those with lower IQ. There were no diﬀerences between patients and
controls for WM volume and there were no signiﬁcant eﬀects by age.
There was, however, an eﬀect of IQ on WM, which did not diﬀer be-
tween groups, with higher IQ showing an association with greater WM
volume. No relationships were observed for cannabis with either GM or
WM volumes in patients or controls.
Our ﬁndings showing a diﬀerent pattern for GM and WM by age at
illness onset are consistent with the ﬁndings of Cropley et al., in which
GM loss in schizophrenia was greatest in early adulthood (mid-20s
onward), while WM loss was most severe at older ages (30s onward)
(Cropley et al., 2017). Nevertheless, we would need a larger sample of
patients with an onset of illness after their mid-30s to be able to con-
clude if WM loss is present in antipsychotic-naïve patients at later ages
of onset. This also accords with diﬀerences in timing of maturational
changes of GM that extend into the mid-20s compared to white matter
where changes continue into the 4th decade (Lebel et al., 2012). The
eﬀect of age and group, and trend-level interaction eﬀect of age and IQ
on GM may also support Kubota et al., who found longitudinal, relative
improvement in IQ to be positively associated with brain volume in
schizophrenia (Kubota et al., 2015).
Only IQ had a direct eﬀect on WM, which was consistent regardless
of cannabis use. Another study of antipsychotic-naïve patients with
schizophrenia found similar results, with a positive association between
IQ and WM and total brain volume, but not GM (Rais et al., 2012).
Because of the diﬀerence in IQ between the groups, where no healthy
controls scored in the very low range, part of the interaction between IQ
and WM may be primarily related to schizophrenia. However, we did
not ﬁnd any group interactions on the relation between IQ and WM,
suggesting that this relationship was not only driven by the patients.
Further, in a study examining GM to WM ratio by age, Bartzokis et al.
(Bartzokis et al., 2003) found group diﬀerences in the GM to WM ratio
that increased with age and suggested this was due to insuﬃcient white
matter growth in schizophrenia patients compared to healthy controls.
Diﬀerences in the trajectories between GM and WM are observed in key
regions implicated in schizophrenia, especially involving association
cortices that mature in adolescence and early adulthood, involving
temporal and frontal regions. Importantly, while GM changes occur into
early adulthood (Gogtay et al., 2004), WM myelination in these regions
continues into mid-adulthood (Benes et al., 1994). This indicates that
assessing structural changes at illness onset should be considered in the
context of the timing of normal brain maturational changes in GM and
WM in diﬀerent regions of the brain (Gogtay et al., 2011).
A major strength of the study is the inclusion of only antipsychotic-
naïve patients with ﬁrst-episode schizophrenia. The antipsychotic-naïve
deﬁnition was strict, not allowing for a single dose of antipsychotic
medication, thus avoiding the confounding eﬀects of antipsychotic
medication on brain structure. Another strength is the wider age range
for inclusion (18–45 years) than most other ﬁrst-episode adult samples,
allowing a more comprehensive examination across age of illness onset.
Fig. 1. Eﬀect of age on grey matter volume in schizophrenia patients and
healthy controls.
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It should be noted that this ﬁrst-episode study was skewed towards the
younger ages of onset, reﬂecting the peak age of illness onset in the
early 20s. We did not have many ﬁrst episode cases after age 40 years,
thus the linear statistical model applied may not have been able to
suﬃciently address the resulting uneven variance across the age dis-
tribution. While the results reﬂect eﬀects of age of onset within an age
range that captures most of the incident cases, future studies should
include both younger illness onset in adolescence (< 18 years) and
older ages of illness onset (> 45 years), which would also enable ex-
amination of the impact of age of onset and interactions with illness and
IQ on the developing and aging brain, respectively. Also, following
these patients and controls longitudinally will allow examination of
trajectories and the dynamic relationships between age, illness, IQ and
brain structure from the antipsychotic-naïve state across the course of
illness.
A limitation to the study was the relatively small sample size, which
is explained by the fact that antipsychotic-naïve ﬁrst-episode schizo-
phrenia patients are challenging to recruit. We therefore cannot exclude
the possibility that some of the negative ﬁndings may be due to a type 2
error. The whole brain GM and WM volume outcome measures used in
this study allowed for an examination of the global eﬀects of age of
onset and interactions with illness, IQ, and cannabis. In order to in-
vestigate the global vs regional nature of these eﬀects and interactions,
a more detailed, e.g. a region of interest (ROI) approach would be re-
quired. However, ROI analyses would require a larger sample size.
Cannabis use did not have an independent eﬀect on the whole brain
GM or WM measures examined in this study, which may in part be due
to our exclusion of patients with diagnosed drug dependency and the
measure of lifetime use applied in this study. The cumulative dose of
cannabis use has been found to have an impact on GM in non-psychotic
heavy users (Yücel et al., 2008), while the age of onset of cannabis use
may be more relevant for eﬀects on WM (Zalesky et al., 2012). It is also
possible that a more speciﬁc ROI approach to GM and WM may have
yielded diﬀerent results, in terms of eﬀects of cannabis, age, and IQ.
Future studies should also examine subcortical regions, especially the
hippocampal formation, as these regions appear to be speciﬁcally af-
fected by cannabis (Ebdrup et al., 2010; Solowij et al., 2013; Yücel
et al., 2008; Zalesky et al., 2012).
In conclusion, this study found diﬀerences between ﬁrst-episode,
antipsychotic-naïve schizophrenia patients and healthy controls on GM,
a general impact of age on GM, and that intelligence has an impact on
Table 3
Bootstrap parameter estimates.
Age, group and IQ eﬀects on GM and WM volume
Dependent variables B (SD) p-Value BCad 95% conﬁdence interval
Grey matter Intercepta 862.25 (5.84) < 0.001 (851.22, 871.59)
Groupb 18.72 (9.11) 0.04 (−0.96, 42.35)
Agec −4.09 (1.12) < 0.001 (−6.28, −2.28)
IQc 2.57 (3.57) 0.46 (−4.16, 8.98)
Age ∗ group 0.30 (1.76) 0.85 (−3.45, 5.63)
Age ∗ IQ 1.03 (0.68) 0.07 (−0.59, 2.24)
Age ∗ group ∗ IQ −0.60 (1.80) 0.57 (−4.27, 0.73)
White matter Intercept 757.89 (5.51) < 0.001 (747.17, 770.51)
Groupb 1.56 (9.01) 0.90 (−14.16, 13.16)
Agec −0.43 (1.50) 0.77 (−2.80, 3.38)
IQc 6.47 (3.10) 0.04 (−0.67, 13.50)
Age ∗ group 2.87 (2.20) 0.15 (−0.97, 4.84)
Age ∗ IQ 0.73 (0.71) 0.18 (−0.53, 2.53)
Age ∗ group ∗ IQ −0.59 (2.08) 0.66 (−4.13, 6.25)
a GM and WM volumes were spatially normalized, corrected for ICV and are reported in mm3.
b Group (0= healthy controls; 1= schizophrenia patients), i.e. positive eﬀects of group indicate larger volumes in controls compared to patients.
c Age and IQ were centered in analyses.
d BCa=Bias-corrected and accelerated bootstrap interval.
Fig. 2. Eﬀect of age on white matter volume in schizophrenia patients and
healthy controls.
Fig. 3. Eﬀect of IQ on white matter volume in schizophrenia patients and
healthy controls.
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WM in both patients and healthy controls.
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